The present invention provides nanoparticles comprising at least one boronic acid compound and at least one stabilizing agent for the at least one boronic acid compound and/or a reaction product of the at least one boronic acid compound and the at least one stabilizing agent, whereby the nanoparticles have a particle size of about 10 to about 1000 nm. The present invention also provides a pharmaceutical composition comprising these nanoparticles and a method for the preparation of these nanoparticlesand the respective pharmaceutical compositions.In addition, the present invention provides nanoparticles and pharmaceutical compositions for the treatment of several disorders, especially multiple myeloma, preferably by parenteral administration.

The present invention provides pharmaceutical compositions comprising a chylomicron and a carotenoid. The present invention also provides pharmaceutical compositions comprising a micelle and a carotenoid, suspended in an aqueous solution and suitable for intravenous administration. The bioavailability of the carotenoid of the pharmaceutical composition is higher relative to the bioavailability of free carotenoid.

The present invention relates to a target specific composition for a photothermal therapy and a photothermal therapy method using the composition and, more specifically, to a photothermal therapy method for selectively killing an inflammatory cell by using a target specific composition for a photothermal therapy including a dextran-coated carbon nanotube. According to the present invention, the composition for a photothermal therapy including a dextran-coated carbon nanotube is absorbed only in an inflammatory cell, which is a wanted target cell, to cause a photothermal therapeutic reaction by a light radiated from an external light source, and does not damage cells except for the inflammatory cell. The photothermal therapy method using the composition for photothermal therapy minimizes side effects, and maximizes a therapeutic effect.

The present invention comprises pegylated TRAIL peptides and their use in conjunction with various TRAIL sensitizing agents in tumor homing nanoparticle formulations for use in the treatment of cancer in a subject.

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.

Formulations of cross-linkable polymers, capable of forming non-toxic and biocompatible hydrogels in situ, containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM), nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.

The present invention generally relates to microfluidics, and to spray drying and other drying techniques. Various embodiments of the invention are generally directed to systems and methods for drying fluids contained within a channel such as a microfluidic channel. For example, a fluid may be partially or completely dried within a microfluidic channel, prior to being sprayed into a collection region. In some embodiments, the fluids may be dried relatively rapidly, resulting in spray-dried particles that are partially or completely amorphous. For instance, the fluid may contain salts, drugs, small molecules, ceramics, inorganic species, metals, sugars, polymers, etc., which may be dried to form partially or completely amorphous nanoparticles containing these species.

The present disclosure provides, in some aspects, nucleic acid nanostructures subsaturated with polyamine polymers. The present disclosure also provides, in some aspects, nucleic acid nanocapsules that include a first nucleic acid nanostructure bound to a second nucleic acid nanostructure through a pH-sensitive interface, thereby forming a nanocapsule having an exterior surface and an interior compartment having an interior surface.

A polypeptide conjugate for use in a method for binding and/or internalization of the polypeptide conjugate to a mammalian cell having a transferrin receptor (TFRC) and/or receptor for advanced glycation end products (RAGE). The polypeptide conjugate may be used in a method for targeting of a drug delivery system or diagnostic delivery system.

Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease.

There is provided a nanoparticle-containing hydrogel comprising metal nanoparticles and at least one peptide. The nanoparticle-containing hydrogel may possess antibacterial activity. There is also provided a method for preparing the nanoparticle-containing hydrogel, and compositions and uses thereof.

Nanostructure conjugates, methods for their preparation, and methods for their use are described. The nanostructure conjugates are useful in inhibiting, activating, and modulating extrasynaptic receptors and ion channels, and in treating various medical conditions among other attractive uses.

The invention provides multivalent surface-crosslinked micelle (SCM) particles, crosslinked reverse micelle (CRM) particles, and methods of making and using them. The SCM particles can be used, for example, to inhibit a virus or bacteria from binding to a host cell. The inhibition can be used in therapy for the flu, cancer, or AIDS. The CRM particles can be used, for example, to prepare metal nanoparticles or metal alloy nanoparticles, or they can be used in catalytic reactions.

[Problem] The purpose of the present invention is to provide an aqueous suspension preparation that comprises a macrolide antibacterial agent as an active component. Specifically, the purpose of the present invention is to provide a pharmaceutical composition that comprises a macrolide antibacterial agent as an active component and that can be put to practical use. [Solution] The present invention provides: an aqueous suspension preparation that is characterized by comprising nanoparticles of a macrolide antibacterial agent and a dispersion stabilizer; an aqueous suspension in which the average particle size of nanoparticles is 500 nm or less and the D90 particle size is 1,500 nm or less; a parenterally administered pharmaceutical composition that comprises this aqueous suspension preparation; an injection preparation; and eye drops or ear drops, more specifically, eye drops for the treatment or prevention of inflammatory diseases of the eye or ear drops for the treatment or prevention of inflammatory diseases of the ear.

The present invention relates to a micelle composition comprising a hydrophobic compound and an amphiphilic block copolymer, wherein the amphiphilic block copolymer consists of a hydrophobic block A and a hydrophilic block B, the hydrophobic block A comprises at least one hydrophobic polymeric unit X and the hydrophilic block B comprises at least one hydrophilic polymeric unit Y whereby the X and Y blocks alternate. The present invention further relates to a process for the preparation of the micelle composition wherein the process comprises the steps of: a) dissolving the hydrophobic compound and the amphiphilic block copolymer in an organic solvent to form a solution, b) adding said organic solution into an aqueous medium, c) optionally repeating aforementioned steps. The micelle composition according to the present invention is useful in medical applications such as therapeutic cardiovascular applications, veterinary applications, food processing applications, flame retardant applications, coatings, adhesives and cosmetics, fabric/textiles, industrial and art applications.

Disclosed herein are polymer nanoparticles comprising i. a nano-precipitated bioactive compound, wherein the nano-precipitate is encapsulated by a lipid, and ii. a hydrophobic bioactive compound. Also provided herein are methods for preparing the nanoparticles and compositions comprising the nanoparticles and methods for the treatment of a disease or an unwanted condition in a subject comprising administering the polymer nanoparticles.

Magnetic iron oxide nanoparticles (MIONs) having silica (SiMION) and gold-silica (AuSiMION) nanoshells, methods of their preparation, and their use in cancer imaging and therapy applications are disclosed.

A method to prepare nanohydrogel comprising the steps of: - hydrophobic functionalization, wherein a polysaccharide is functionalized with a hydrophobic compound; self-assembling, wherein the functionalized polysaccharide obtained from the preceding step is subject to a self- assembling process in a water environment for the formation of nanohydrogel. The hydrophobic compound is riboflavin, or a derivative thereof, to which an alkyl group having a functional group suited to form a covalent bond with the polysaccharide has been bonded.

A method produces polymer nanoparticles. Polymer solution is sprayed through a nozzle toward a collector. An electric field is created at the nozzle, such as by a voltage is applied to the nozzle to create the electric field. The voltage applied to the nozzle is from ~10(Kilovolt) to ~30(Kilovolt), distance from nozzle tip to collector is from ~1(centimeter) to ~10 (centimeter) and the polymer concentration from ~0.01% to ~0.5% w/w. Preferably a grounded liquid collectors is used. The invention provides biocompatible monodisperse polymer nanoparticles having a size of less than ~300nm, preferably less than ~150nm. Payloads can be associated, and maintain efficacy, including more than one payload such as therapeutic agents and diagnostic agents on the same particles. Preferred particles are poly(methyl methacrylate) (PMMA-COOH) or acrylate analogues.

The present invention provides a transdermal solution agent which is obtained by colloidally dispersing a medicament or a salt thereof and phosphatidylcholine in propylene glycol or a propylene glycol-containing solution, and which exhibits excellent skin permeability of the medicament, while being reduced in the problem of skin irritation. A solution agent of the present invention has a modal value of particle diameters of around 100 nm, and has an average particle diameter within the range of 50-500 nm. The solution agent of the present invention achieves exponentially improved skin permeability by additionally containing an absorption enhancer such as triethanolamine.

The present invention relates to the discovery that mesoporous silica nanoparticles may be modified in pore size from the natural mesophase by generating mesoporous materials in binary, ternary or multiphase surfactant systems to produce biphasic, triphasic or multiphase mesophorous structures. Thus, the present invention relates to methods of producing biphase, triphasic and multiphase mesoporous stuctures with finely tuned mesopore size and protocells which are produced therefrom and mesoporous silica nanoparticles obtained therefrom. The resulting mesoporous nanostructures may be used to create protocells having unique cargo loading and release characteristics. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.

Disclosed herein are prodrugs of platinum containing anticancer agents such as cisplatin that contain an alkylating moiety. Upon administration, the prodrugs release the platinum containing anticancer agent and the alkylating agent, which can form an adduct with DNA or can protect the platinum containing agent from removal. The disclosed prodrugs can be used to treat various cancers, including cisplatin resistant cancers.

Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non- covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule. Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence

The present disclosure relates to a method for the preparation of a nanosuspension of at least one natural material, wherein the method comprises the steps of (a) providing at least one natural material having a particle size (D90) of less than 320 μm; (b) dispersing said at least one natural material of step (a) in a solvent; and (c) milling the dispersion of step (b) to a particle size (D90) of below 1000 nm. The nanosuspension is useful for the preparation of a medicament.

The present invention concerns nanoparticles functionalized with duplex RNA for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a new strategy for conjugating RNA to a nanoparticle to achieve increased stability and activity.